Encompass Health (EHC) Expected to Announce Quarterly Earnings on Thursday

Encompass Health (NYSE:EHC - Get Free Report) will likely be releasing its Q1 2025 earnings data after the market closes on Thursday, April 24th. Analysts expect the company to announce earnings of $1.19 per share and revenue of $1.43 billion for the quarter. Encompass Health has set its FY 2025 guidance at 4.670-4.960 EPS.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $1.17 EPS for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. On average, analysts expect Encompass Health to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Encompass Health Stock Down 6.9 %

EHC stock traded down $7.16 during midday trading on Monday, reaching $96.19. 1,704,046 shares of the company were exchanged, compared to its average volume of 670,639. The stock's 50-day simple moving average is $99.87 and its 200 day simple moving average is $98.30. Encompass Health has a 1-year low of $79.26 and a 1-year high of $104.55. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The company has a market cap of $9.69 billion, a price-to-earnings ratio of 21.57, a price-to-earnings-growth ratio of 2.31 and a beta of 0.87.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st were paid a dividend of $0.17 per share. The ex-dividend date of this dividend was Tuesday, April 1st. This represents a $0.68 annualized dividend and a yield of 0.71%. Encompass Health's dividend payout ratio is currently 15.25%.

Insider Activity

In other Encompass Health news, CAO Andrew L. Price sold 5,042 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the sale, the chief accounting officer now directly owns 69,164 shares in the company, valued at approximately $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.10% of the company's stock.

Analysts Set New Price Targets

EHC has been the topic of a number of research analyst reports. Barclays lifted their target price on Encompass Health from $116.00 to $118.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research report on Friday, February 7th. StockNews.com downgraded Encompass Health from a "buy" rating to a "hold" rating in a report on Wednesday, April 16th. KeyCorp upped their price target on shares of Encompass Health from $117.00 to $120.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $110.00 target price on shares of Encompass Health in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Encompass Health presently has an average rating of "Buy" and an average target price of $107.67.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.